nature portfolio

Corresponding author(s):	Muthiah Kumaraswami
Last updated by author(s):	Sep 3, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

o.			
St	at	ıstı	$1 \cap S$

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed		
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
\boxtimes	A description of all covariates tested		
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>		
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
\boxtimes	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code			
Policy information about <u>availability of computer code</u>			
Da	ata collection No custom software was used for data collection.		

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\mathsf{policy}}$

Data supporting the findings of this study are available in this article and its Supplementary Information files, or from the corresponding author upon request. Genomes of S. salivarius K12 and MGAS10870 were sequenced previously, and sequences are publicly available. Primers used in this study are provided in Supplementary Table 2. Minimum datasets that are necessary to interpret, verify, and extend the research in the article are provided as source data with this paper.

No custom software or algorithms were used for data analysis. Graphpad prism was used for data analysis and statistical significance among

Field	d-specific	reporting

Please select the on	e below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences			
For a reference copy of th	ne document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scien	ces study design		
All studies must disc	close on these points even when the disclosure is negative.		
Sample size	For in vitro and ex vivo experiments, 3 biological replicates were analyzed in duplicates. For in vivo experiments, 10 or more animals were used for each group. No statistical method was used to predetermine sample size.		
Data exclusions	No data exclusions.		
Replication	Experiments were performed using 3 biological replicates that were analyzed in duplicates and data from biological replicates were consistent with each other.		
Randomization	als were assigned randomly to different experimental groups. Random allocation was not relevant for in vitro experiments as vast rity of the experiments compare the effects of different mutant strains.		
Blinding	Animal infection experiments were performed in a blinded fashion. The investigators were blinded for the group assignment in animal infection studies. All biological samples were processed and analyzed blindly regarding the experimental groups.		
Reporting	g for specific materials, systems and methods		
	n from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	erimental systems Methods		
n/a Involved in the			
Antibodies	ChIP-seq		
Eukaryotic o			
	gy and archaeology MRI-based neuroimaging I other organisms		
	earch participants		
Clinical data			
	search of concern		
Antibodies			
Antibodies used	Antibodies raised against recombinant SpeB protease was used to detect secreted SpeB levels. Anti SpeB primary antibodies were used at 1:100,000 dilution, whereas the secondary antibodies were used at 1:50,000 dilution. Antirabbit HRP-conjugated secondary antibodies were purchased from Thermo Scientific (Catalog no. SA1-9510).		
Validation	The antibody was used in several previously published studies and validated for its specific binding to SpeB. SpeB-specific reactivity and lack of cross reactivity of anti SpeB antibodies with other GAS proteins were verified in previous published studies.		
Animals and	other organisms		
Policy information a	bout <u>studies involving animals</u> ; <u>ARRIVE guidelines</u> recommended for reporting animal research		
Laboratory anima	CD-1 mice, 3-10 weeks old, female mice/ C57BL/6 mice, 4-6 weeks old, female mice		
Wild animals	None		
Field-collected sar	mples None		
Ethics oversight	Houston Methodist Research Institute IACUC, and Emory School of Medicine IACUC Full information of the committee, study protocol, and approved protocol numbers are provided in the manuscript.		

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.